Compound of Formula for use in the treatment of cancer, autoimmune disease, inflammatory disease, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cardiovascular diseases, allergies, asthma, Alzheimer's disease, hormone-related diseases, rheumatoid arthritis, and solid and hematologic malignancies, whereby the compound of Formula is administered to a patient in a therapeutically effective amount: wherein: R 1 is NR 4 R 5, optionally substituted C 1 to C 6 alkoxy, optionally substituted C 6 to C 14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl, wherein: (i) 3-4 membered cycloalkyl and heterocyclyl are saturated; (ii) hydrogen atoms on the same carbon atom of said cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (iii) hydrogen atoms on the same atom of said cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent; R 2 is optionally substituted phenyl, -O-(C 1 to C 6 alkyl)-optionally substituted phenyl, or optionally substituted 5-6 membered heteroaryl, with the proviso that when R 2 is 4-pyridyl, the 4-pyridyl lacks a carbonyl substituent at the 2 nd position; R 4 and R 5 are: (a) independently selected from the group consisting of H, C 1 to C 6 alkyl, C 1 to C 6 hydroxyalkyl, C 3 to C 8 cycloalkyl, and -(C 1 to C 6 alkyl)N(C 1 to C 6 alkyl)(C 1 to C 6 alkyl); or (b) joined to form an optionally substituted 3-8 membered heterocyclyl, wherein; (bi) hydrogen atoms on the same carbon atom of said heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (bii) hydrogen atoms on the same atom of said heterocyclyl (b), cycloalkyl (bi), or heterocyclyl (bi), are optionally replaced with O to form an oxo substituent; or a pharmaceutically acceptable salt or ester thereof. R 1 is NR 4 R 5, optionally substituted C 1 to C 6 alkoxy, optionally substituted C 6 to C 14 aryl, optionally substituted heteroaryl, optionally substituted 3-10 membered monocyclic or bicyclic cycloalkyl, or optionally substituted 3-10 membered monocyclic or bicyclic heterocyclyl, wherein: (i) 3-4 membered cycloalkyl and heterocyclyl are saturated; (ii) hydrogen atoms on the same carbon atom of said cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (iii) hydrogen atoms on the same atom of said cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent; (i) 3-4 membered cycloalkyl and heterocyclyl are saturated; (ii) hydrogen atoms on the same carbon atom of said cycloalkyl or heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (iii) hydrogen atoms on the same atom of said cycloalkyl or heterocyclyl are optionally replaced with O to form an oxo substituent; R 2 is optionally substituted phenyl, -O-(C 1 to C 6 alkyl)-optionally substituted phenyl, or optionally substituted 5-6 membered heteroaryl, with the proviso that when R 2 is 4-pyridyl, the 4-pyridyl lacks a carbonyl substituent at the 2 nd position; R 4 and R 5 are: (a) independently selected from the group consisting of H, C 1 to C 6 alkyl, C 1 to C 6 hydroxyalkyl, C 3 to C 8 cycloalkyl, and -(C 1 to C 6 alkyl)N(C 1 to C 6 alkyl)(C 1 to C 6 alkyl); or (b) joined to form an optionally substituted 3-8 membered heterocyclyl, wherein; (bi) hydrogen atoms on the same carbon atom of said heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (bii) hydrogen atoms on the same atom of said heterocyclyl (b), cycloalkyl (bi), or heterocyclyl (bi), are optionally replaced with O to form an oxo substituent; (a) independently selected from the group consisting of H, C 1 to C 6 alkyl, C 1 to C 6 hydroxyalkyl, C 3 to C 8 cycloalkyl, and -(C 1 to C 6 alkyl)N(C 1 to C 6 alkyl)(C 1 to C 6 alkyl); or (b) joined to form an optionally substituted 3-8 membered heterocyclyl, wherein; (bi) hydrogen atoms on the same carbon atom of said heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (bii) hydrogen atoms on the same atom of said heterocyclyl (b), cycloalkyl (bi), or heterocyclyl (bi), are optionally replaced with O to form an oxo substituent; (bi) hydrogen atoms on the same carbon atom of said heterocyclyl are optionally replaced with an optionally substituted 3-6 membered cycloalkyl or heterocyclyl to form a spirocycloalkyl or spiroheterocyclyl; and (bii) hydrogen atoms on the same atom of said heterocyclyl (b), cycloalkyl (bi), or heterocyclyl (bi), are optionally replaced with O to form an oxo substituent;